MDACC Study No:2006-0358 ( NCT No: NCT00398983)
Title:Randomized study of decitabine versus observation as maintenance therapy for adults with unfavorable risk AML in first CR or adults with relapsed AML in second or greater CR
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Decitabine
Study Status:Terminated
Study Description:The goal of this clinical study is to find out whether continued therapy with
decitabine after achieving a remission in AML patients can help prolong the
remission and prevent relapse of the disease.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II/Phase III
Treatment Agents:Decitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:No hospitalization
Supported By:N/A
Return Visit:every 3 to 6 months
Home Care:After the first course, the study treatment may be given at home. Patients on
the observation arm of the study may receive treatment at the discretion of
their physician.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults